Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse
Authors:
- 1 February 2017
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 72, 12-19
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialThe Lancet Haematology, 2016
- Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC networkNeuro-Oncology, 2016
- Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre StudyBritish Journal of Haematology, 2016
- Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish–Swedish Population-Based StudyJournal of Clinical Oncology, 2015
- Randomized phase III study of whole-brain radiotherapy for primary CNS lymphomaNeurology, 2015
- Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2014
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaJournal of Clinical Oncology, 2005